ライフサイエンスコーパス: cerebrovascular disease

1 for cardiac disease, metabolic syndrome, and cerebrovascular disease.

2 ial cell-derived exosomes in atherosclerotic cerebrovascular disease.

3 ld be useful for treatment and prevention of cerebrovascular disease.

4 ly onset of TAAD and occlusive moyamoya-like cerebrovascular disease.

5 lin sensitivity, might benefit patients with cerebrovascular disease.

6 ndependent from glucose levels, that lead to cerebrovascular disease.

7 cribed for patients with coronary artery and cerebrovascular disease.

8 may offer a potential therapeutic target in cerebrovascular disease.

9 cans that most commonly reflect small vessel cerebrovascular disease.

10 team, pancreas cold ischemia time, recipient cerebrovascular disease.

11 associated with increased cardiovascular and cerebrovascular disease.

12 rologic diagnosis, particularly headache and cerebrovascular disease.

13 ted by markers of both neurodegeneration and cerebrovascular disease.

14 BP produced by treatment among patients with cerebrovascular disease.

15 ssociation between vitamin D and subclinical cerebrovascular disease.

16 an increasing developmental basis for human cerebrovascular disease.

17 k for dementia later in life, independent of cerebrovascular disease.

18 ventricular arrhythmias, heart failure, and cerebrovascular disease.

19 eased risk of clinical stroke or subclinical cerebrovascular disease.

20 sorders should be targeted by treatments for cerebrovascular disease.

21 demia, diabetes, coronary heart disease, and cerebrovascular disease.

22 volved, especially in the absence of obvious cerebrovascular disease.

23 e, such as headache and neuroinflammatory or cerebrovascular disease.

24 ronic atrial fibrillation and peripheral and cerebrovascular disease.

25 s those with coronary heart disease (CHD) or cerebrovascular disease.

26 , two fundamental challenges in the field of cerebrovascular disease.

27 a 1 gene (COL4A1) cause dominantly inherited cerebrovascular disease.

28 n patients presenting with symptoms of acute cerebrovascular disease.

29 llelic series of COL4A1 mutations that cause cerebrovascular disease.

30 tion much like mutations that cause familial cerebrovascular disease.

31 rvation of gait speed in elderly people with cerebrovascular disease.

32 ld cognitive impairment maps more closely to cerebrovascular disease.

33 n to higher BMI did not increase the risk of cerebrovascular disease.

34 as, and cognitively unimpaired patients with cerebrovascular disease.

35 ltered also in dementias related, or not, to cerebrovascular disease.

36 be taking a statin versus those with CHD or cerebrovascular disease.

37 baseline LDL-C concentration and history of cerebrovascular disease.

38 spective of baseline LDL-C and of history of cerebrovascular disease.

39 re severe baseline upper-limb disability and cerebrovascular disease.

40 le for myeloperoxidase in the progression of cerebrovascular disease.

41 ment of pregnancy, and strategies to prevent cerebrovascular disease.

42 gly associated with concomitant coronary and cerebrovascular diseases.

43 s, history of CVA, hyperlipidemia, and other cerebrovascular diseases.

44 in the research, diagnosis, and treatment of cerebrovascular diseases.

45 development and a potential drug target for cerebrovascular diseases.

46 ed to train physicians specifically to treat cerebrovascular diseases.

47 that migraine increases the overall risk of cerebrovascular diseases.

48 thromboembolic disease, aortic disease, and cerebrovascular diseases.

49 flammatory, neurodegenerative, traumatic and cerebrovascular diseases.

50 s to neuronal injury during stroke and other cerebrovascular diseases.

51 parameter for treatment decisions in chronic cerebrovascular diseases.

52 n clinical application on cardiovascular and cerebrovascular diseases.

53 nt of therapeutics for neuroinflammatory and cerebrovascular diseases.

54 6 x (renal insufficiency) + 0.46 x (previous cerebrovascular disease) + 0.352 x (prior tobacco use) +

55 on, 0.77 (95% CI: 0.65 to 0.93) for ischemic cerebrovascular disease, 0.71 (95% CI: 0.58 to 0.88) for

56 4-1.98), and tuberculosis (1.26, 1.08-1.48); cerebrovascular disease (1.09, 1.04-1.14) and ischaemic

57 ogressive supranuclear palsy (6.4%; n = 13), cerebrovascular diseases (1%; n = 2), amyotrophic latera

58 , congestive heart failure 2.65 (2.29-3.06), cerebrovascular disease 10.02 (9.08-11.05), insulin ther

59 VD deaths), hypertensive diseases (27%), and cerebrovascular diseases (10%).

60 ry artery disease (30.0%, 32.9%, and 34.3%), cerebrovascular disease (11.7%, 10.8%, and 17.6%), and v

61 0.003); was more frequently associated with cerebrovascular disease (11.8% versus 6.0%, p = 0.006),

62 h a partner (3.16; 2.71-3.69), those without cerebrovascular disease (2.23; 2.08-2.39), and those wit

63 eaths, with ischemic heart disease (31%) and cerebrovascular diseases (30%) being the leading CVD cau

64 235.7 deaths per 100000 persons) and 1.7 for cerebrovascular disease (40.3 vs 68.1 deaths per 100000

65 with MPN versus controls (16.8% v 15.2%) or cerebrovascular disease (5.6% v 5.2%).

66 itourinary infection (10.1%), sepsis (7.1%), cerebrovascular disease (5.8%), and pulmonary embolism (

67 S caused the most deaths (29.1%) followed by cerebrovascular disease (7.5%) and lower respiratory inf

68 , a 1.20-fold (95% CI: 1.15, 1.25) hazard of cerebrovascular disease, a 2.14-fold (95% CI: 2.06, 2.22

69 0.72; 95% CI: 0.55 to 0.94; p = 0.02), acute cerebrovascular disease (adjusted OR: 0.36; 95% CI: 0.31

70 dependent risk factor for cardiovascular and cerebrovascular diseases (adjusted HR, 2.27 [95% CI, .97

71 gic measures; however, high CLS men had less cerebrovascular disease after accounting for vascular ri

72 Ischemic heart disease and cerebrovascular disease age-standardized death rates (as

73 irment in LLD seems to be related to greater cerebrovascular disease along with abnormalities in immu

74 Cerebrovascular disease and Alzheimer disease (AD) frequ

75 opathological studies have demonstrated that cerebrovascular disease and Alzheimer disease (AD) patho

76 ation counteracts the deleterious effects of cerebrovascular disease and Alzheimer's disease and high

77 on pathologies associated with brain ageing, cerebrovascular disease and Alzheimer's disease, and par

78 4 patients (5.0%) with a history of previous cerebrovascular disease and among those without a histor

79 ife remains a major concern, with death from cerebrovascular disease and cardiovascular disease accou

80 ions of neurodegenerative abnormalities with cerebrovascular disease and cognitive performance indica

81 ty and efficacy of endovascular treatment of cerebrovascular disease and concerns in anesthesia manag

82 of the association between these lesions and cerebrovascular disease and dementia.

83 col designed to obtain a cohort enriched for cerebrovascular disease and elevated vascular risk.

84 prevalent in people with clinically manifest cerebrovascular disease and have been shown to increase

85 n addition to Alzheimer's disease, including cerebrovascular disease and hippocampal sclerosis.

86 ular COL4A1, or both, contribute to sporadic cerebrovascular disease and ICH.

87 of hypertonic saline in patients with severe cerebrovascular disease and impending intracranial hyper

88 system disorders, including highly penetrant cerebrovascular disease and intracerebral hemorrhage (IC

89 Covert cerebrovascular disease and its consequences on cognitiv

90 vascular aging, the greatest risk factor for cerebrovascular disease and its subsequent effects.

91 novel approaches to slow the progression of cerebrovascular disease and lessen both the frequency an

92 heart failure, or combination of preexisting cerebrovascular disease and mild cognitive impairment in

93 lure, earlier era of transplant, preexisting cerebrovascular disease and no previous malignancy.

94 VD), including coronary heart disease (CHD), cerebrovascular disease and peripheral arterial disease.

95 ar disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease.

96 ]) and other atheromatous outcomes (ischemic cerebrovascular disease and peripheral vascular disease)

97 function among individuals with established cerebrovascular disease and preserved estimated glomerul

98 have documented a close relationship between cerebrovascular disease and risk of Alzheimer's disease.

99 d provide insight into inflammation-mediated cerebrovascular disease and stroke.

100 c, studies on the role of the Hp genotype in cerebrovascular disease and the implications for worseni

101 15 provinces had cerebrovascular disease and two (Hong Kong and Macao) ha

102 ressants (n = 420,280; 59.7% female) to have cerebrovascular disease and use anxiolytic or antipsycho

103 Cerebrovascular disease and vascular risk factors are as

104 al hypertension, previous cardiovascular and cerebrovascular diseases and dementia.

105 od-brain barrier (BBB) dysfunction occurs in cerebrovascular diseases and neurodegenerative disorders

106 technology has a great impact on research in cerebrovascular diseases and still has various applicati

107 plications for patients with rare congenital cerebrovascular diseases and their families.

108 rterial disease, 1.32 (95% CI 1.15-1.50) for cerebrovascular disease, and 1.93 (95% CI 1.47-2.53) for

109 alization for or death from CHD, 25 426 from cerebrovascular disease, and 249 426 from hypertensive d

110 emic heart disease, 1,064 developed ischemic cerebrovascular disease, and 3,807 died during follow-up

111 heart failure, 84% had hypertension, 30% had cerebrovascular disease, and 8% had dementia.

112 lar disease: 345 coronary heart disease, 117 cerebrovascular disease, and 98 peripheral arterial dise

113 diabetes, dementia, ischaemic heart disease, cerebrovascular disease, and cancer because of increased

114 e matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid beta-am

115 ation class III/IV, antiarrhythmic drug use, cerebrovascular disease, and chronic kidney disease stag

116 id congestive heart failure, cardiomyopathy, cerebrovascular disease, and chronic lung disease.

117 Risk of CHD, cerebrovascular disease, and heart failure in normal wei

118 had a higher risk of coronary heart disease, cerebrovascular disease, and heart failure than normal w

119 We examined CHD, cerebrovascular disease, and hypertensive disease risks

120 art disease, myocardial infarction, ischemic cerebrovascular disease, and ischemic stroke, with a cor

121 The pathologic indices of Alzheimer disease, cerebrovascular disease, and Lewy body disease accumulat

122 lure, earlier era of transplant, preexisting cerebrovascular disease, and no previous malignancy.

123 ed decreased risk of coronary heart disease, cerebrovascular disease, and overall CVD mortality in Ch

124 re followed for ASCVD events comprising CHD, cerebrovascular disease, and PAD events until December 3

125 ease, which included coronary heart disease, cerebrovascular disease, and peripheral arterial disease

126 mong patients with PAD and CHD, with PAD and cerebrovascular disease, and with CHD and cerebrovascula

127 on; white matter lesions (WMLs), a marker of cerebrovascular disease; and cognitive functions.

128 ve had previous revascularization or carotid/cerebrovascular disease; and were more likely to have th

129 The consequences of cerebrovascular disease are among the leading health iss

130 INTRODUCTION: Patients with cerebrovascular disease are at increased risk for cognit

131 Cardiac and cerebrovascular diseases are currently the leading cause

132 ffects, their mechanisms and implications in cerebrovascular diseases are not known.

133 Cerebrovascular diseases are the most common neurologica

134 Prior cardiovascular or cerebrovascular disease, arterial hypotension at admissi

135 o a growing body of evidence that implicates cerebrovascular disease as a core feature of AD and not

136 By 2013, 27 provinces had cerebrovascular disease as the leading cause, five had i

137 e immune signalling in the pathogenesis of a cerebrovascular disease, as well as strategies for its t

138 Cerebrovascular disease associated with ACTA2 mutations

139 ons found in inflammatory cardiovascular and cerebrovascular diseases associated with an elevated blo

140 d not have other clinical evidence of AF and cerebrovascular disease at baseline.

141 between major depressive disorder (MDD) and cerebrovascular disease at the cellular level.

142 ure, and status with respect to coronary and cerebrovascular diseases, atrial fibrillation, smoking,

143 tain incident CVD (coronary heart disease or cerebrovascular disease) between the survey and the end

144 diseases--namely, type 2 diabetes, dementia, cerebrovascular disease, breast cancer, colorectal cance

145 rence to the MeDi is associated with reduced cerebrovascular disease burden.

146 1 mg/m(3) would have had a similar impact on cerebrovascular disease but one only half as great on is

147 vascular depression hypothesis, subclinical cerebrovascular disease can cause depression in older ad

148 Microvascular disease, diabetic foot, cerebrovascular disease, cardiovascular disease, acute m

149 avian stenosis, peripheral vascular disease, cerebrovascular disease, cardiovascular disease, or surv

150 of major coronary heart disease (CHD) and/or cerebrovascular disease (CBD) events in a large cohort o

151 groups with incidence of and mortality from cerebrovascular disease (CBVD) in a Mediterranean popula

152 re significantly higher for 18 patients with cerebrovascular disease (CeVD) than for 18 age- and gend

153 blood pressure, blood urea nitrogen, sodium, cerebrovascular disease, chronic obstructive pulmonary d

154 The prevalence of diabetes, hypertension, cerebrovascular disease, chronic obstructive pulmonary d

155 k of mortality from ischaemic heart disease, cerebrovascular disease, chronic obstructive pulmonary d

156 of participants with no clinical evidence of cerebrovascular disease: cognitively normal (CN) without

157 ave higher rates of cognitive impairment and cerebrovascular disease compared with uninfected populat

158 disease, heart failure, cardiac arrhythmia, cerebrovascular disease, congenital heart disease, or ad

159 a low, intermediate or high likelihood that cerebrovascular disease contributed to cognitive impairm

160 CD; e.g. prior CNS opportunistic infection), cerebrovascular disease (CVD) and HIV-associated neuroco

161 ion of apolipoprotein E (APOE) genotype with cerebrovascular disease (CVD) in a large neuropathologic

162 Cerebrovascular disease (CVD) is consistently associated

163 between various mental illnesses and cardio-cerebrovascular disease (CVD) risk, few have compared th

164 RCD; eg, prior CNS opportunistic infection), cerebrovascular disease (CVD), and HAND.

165 were acute myocardial infarction (MI), acute cerebrovascular disease (CVD), major bleeding, and all-c

166 sease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]) on long-term cardiovascul

167 Cardiovascular and cerebrovascular diseases (CVDs) related to overwork are

168 whereas Mexicans experienced higher rates of cerebrovascular disease deaths.

169 europathological examination with or without cerebrovascular disease, defined neuropathologically.

170 y of heart failure, coronary artery disease, cerebrovascular disease, diabetes mellitus, hypertension

171 ed more sub-phenotypes of cardiovascular and cerebrovascular diseases (e.g., angina pectoris, heart f

172 ity burden of hypertensive heart disease and cerebrovascular disease, especially hemorrhagic stroke,

173 and the new occurrence of cardiovascular and cerebrovascular disease, especially the brain infarction

174 e same role in predicting cardiovascular and cerebrovascular diseases, especially in China.

175 9-23; specificity 96%, 94-98); pre-existing cerebrovascular disease (five cohorts; RR 1.6, 1.1-2.4;

176 ate life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation an

177 The relation with cerebrovascular disease has not yet been closely examine

178 d ratio, 2.02; 95% CI, 1.02-3.97), and prior cerebrovascular disease (hazard ratio, 2.04; 95% CI, 1.0

179 presentations (coronary heart disease [CHD], cerebrovascular disease, heart failure, and peripheral v

180 Thal phase, Braak stage, cerebrovascular disease, hippocampal sclerosis and Patho

181 tributions of Alzheimer's disease pathology, cerebrovascular disease, hippocampal sclerosis and the a

182 re (HR 3.77, 95% CI: 1.79-7.95; P = 0.0005), cerebrovascular disease (HR 3.45, 95% CI: 1.72-6.92; P =

183 s not associated with an increased hazard of cerebrovascular disease (HR, 0.96; 95% CI, 0.65-1.41; P

184 t disease (HR, 1.16; 95% CI, 1.10-1.23), and cerebrovascular disease (HR, 1.15; 95% CI, 1.03-1.28).

185 Cerebrovascular disease (HR, 1.3; 95% CI, 1.2-1.4), chro

186 ted diagnoses (HR, 1.65; 95% CI, 1.26-2.17), cerebrovascular disease (HR, 1.95; 95% CI, 1.14-3.33), p

187 95% confidence interval [CI]: 1.45 to 1.54), cerebrovascular disease (HR: 1.07; 95% CI: 1.04 to 1.11)

188 ase (PVD), diabetes, ischemic heart disease, cerebrovascular disease, hypertension, and smoking, were

189 e diabetes mellitus, ischemic heart disease, cerebrovascular disease, hypertension, and smoking.

190 The findings highlight the prevalence of cerebrovascular disease in adults with DS and add to a g

191 scular disease were older than those without cerebrovascular disease in all the groups except for tho

192 This results in an increased burden of cerebrovascular disease in CKD patients, who consistentl

193 g of the epidemiology and pathophysiology of cerebrovascular disease in CKD.

194 Given the role of cerebrovascular disease in dementia risk, geographic pat

195 ifestyle was associated with protection from cerebrovascular disease in men, but there was no evidenc

196 The possible increased risk of acute cerebrovascular disease in patients with dual infection

197 to the post-mortem assessment and scoring of cerebrovascular disease in relation to vascular cognitiv

198 ed a genetic component to the development of cerebrovascular disease in SCA, but few candidate geneti

199 ci for future functional investigations into cerebrovascular disease in sickle cell anemia.

200 their respective lesions than those without cerebrovascular disease in the context of comparable sev

201 vale (PFO), ischemic stroke, and subclinical cerebrovascular disease in the general population.

202 ts with DS are rare, allowing examination of cerebrovascular disease in this population and insight i

203 and the new occurrence of cardiovascular and cerebrovascular diseases in the study.

204 rt disease, peripheral arterial disease, and cerebrovascular disease, in an elderly male cohort.

205 hite matter hyperintensities, a biomarker of cerebrovascular disease, in several brain areas.

206 1 and COL4A2 cause Mendelian eye, kidney and cerebrovascular disease including intracerebral haemorrh

207 associations between neuroimaging markers of cerebrovascular disease, including lesion topography and

208 igh blood pressure (BP) is a risk factor for cerebrovascular disease, including stroke.

209 L4A1 or COL4A2 mutations suffer from diverse cerebrovascular diseases, including cerebral microbleeds

210 Depression and cerebrovascular disease influence each other, according

211 The extent to which cerebrovascular disease influences the progression of AD

212 Cerebrovascular disease involves various medical disorde

213 Cerebrovascular disease is 1 of the possible mechanisms

214 PURPOSE OF REVIEW: Cerebrovascular disease is a common cause of death and d

215 Concurrent cerebrovascular disease is a common neuropathological fi

216 Comorbidity of AD/SDAT and various types of cerebrovascular disease is a major theme in dementia res

217 Unexpectedly, acute cerebrovascular disease is also emerging as an important

218 Dementia associated with cerebrovascular disease is common.

219 Inflammation that contributes to acute cerebrovascular disease is driven by the proinflammatory

220 diseases, including ischemic heart disease, cerebrovascular disease, ischemic stroke, hemorrhagic st

221 from a distant embolism rather than in situ cerebrovascular disease, leading to the recent formulati

222 cerebral alpha-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genoty

223 'Vascular Depression' hypothesis posits that cerebrovascular disease may predispose, precipitate or p

224 D (MI, IS, PAD, and CVD death), coronary and cerebrovascular disease (MI, IS, CVD death), and individ

225 h an increased risk of incident coronary and cerebrovascular disease morbidity and mortality.

226 [CI, 0.68 to 0.90]; P for trend < 0.001) and cerebrovascular disease mortality (HR, 0.70 [CI, 0.55 to

227 ease, two studies on both coronary heart and cerebrovascular disease mortality and one study on perip

228 France has the lowest present-day cerebrovascular disease mortality for both males and fem

229 Analysis of cerebrovascular disease mortality revealed that Austria

230 The melanoma, NHL, and cerebrovascular disease mortality risks are possibly due

231 re consistent for coronary heart disease and cerebrovascular disease mortality.

232 harmful) to the risk for cardiovascular and cerebrovascular disease, mortality, or all-cause mortali

233 We identified no increased risk of cerebrovascular disease, myocardial infarction, or major

234 DS cancer, chronic renal failure, cardio and cerebrovascular disease, obesity, cachexia or hyperchole

235 r, chronic renal failure, cardiovascular and cerebrovascular disease, obesity, undernutrition, or hyp

236 Progressive cerebrovascular disease occurred in those continuing dia

237 diseases of the heart, malignant neoplasms, cerebrovascular diseases) of the top 4 leading causes of

238 ase, previous myocardial infarction, angina, cerebrovascular disease, older age, and male gender.

239 insurance who had a history of PAD, CHD, or cerebrovascular disease on December 31, 2014.

240 hese differences were associated with covert cerebrovascular disease on magnetic resonance imaging (M

241 ents with PAD only (33.9%) versus those with cerebrovascular disease only (43.0%) or CHD only (51.7%)

242 among patients with PAD only, CHD only, and cerebrovascular disease only was 34.7 (95% CI: 33.2 to 3

243 c retinopathy OR macular edema AND stroke OR cerebrovascular disease OR coronary artery disease OR he

244 and discharged alive and free of documented cerebrovascular disease or preexisting atrial fibrillati

245 (odds ratio [OR], 0.31; 95% CI, 0.12-0.80), cerebrovascular disease (OR, 0.10; 95% CI, 0.01-0.78), c

246 ng disease (OR, 1.215; 95% CI, 1.125-1.312), cerebrovascular disease (OR, 1.172; 95% CI, 1.076-1.276)

247 diovascular disease, ischemic heart disease, cerebrovascular disease, or cardiac arrest associated wi

248 rrespective of baseline LDL-C and history of cerebrovascular disease, over a median follow-up of 2.8

249 ion (P = 0.52), history of cardiovascular or cerebrovascular disease (P = 0.94) and dementia (P = 0.7

250 r risks of coronary heart disease (P=0.002), cerebrovascular disease (P<0.001), and venous thromboemb

251 disease and among those without a history of cerebrovascular disease (P(interaction)=0.37).

252 ars for the outcomes coronary heart disease, cerebrovascular disease, peripheral arterial disease, an

253 or shock, left main coronary artery disease, cerebrovascular disease, peripheral arterial disease, co

254 ars; 81% male) with coronary artery disease, cerebrovascular disease, peripheral artery disease, or a

255 namic state or shock, several comorbidities (cerebrovascular disease, peripheral vascular disease, co

256 BMI), waist-to-hip ratio (WHR), and multiple cerebrovascular disease phenotypes.

257 forms of cognitive disorder associated with cerebrovascular disease, regardless of the specific mech

258 Cerebrovascular diseases represent up to 22% of secondar

259 a (NHL) (RR = 2.69; 95% CI: 1.33, 5.45), and cerebrovascular disease (RR = 1.49; 95% CI: 1.11, 2.01).

260 mes in patients with and without symptomatic cerebrovascular disease (sCVD) undergoing heart transpla

261 impairment (VCI) is a heterogeneous group of cerebrovascular diseases secondary to large and small ve

262 e impairment and suggests that the impact of cerebrovascular disease should be considered with respec

263 s (SMR, 5.31; AER, 13.90; n=11) and included cerebrovascular disease (SMR, 21.72; AER, 7.43; n=5) and

264 We hypothesize that cerebrovascular disease, specifically brain large artery

265 n in autonomic control of the vasculature in cerebrovascular disease states.

266 y accompanied by other neuropathology, often cerebrovascular disease such as brain infarcts.

267 cted patients that are at risk of developing cerebrovascular disease, such as ischemic stroke.

268 ic resonance imaging (MRI) manifestations of cerebrovascular disease, such as lacunes and white matte

269 an important role in the pathophysiology of cerebrovascular diseases-such as blood pressure and oxid

270 rt disease, venous thromboembolic event, and cerebrovascular disease than inactivity.

271 ease showed a lower prevalence of coincident cerebrovascular disease than patients with Alzheimer's d

272 nd cerebrovascular disease, and with CHD and cerebrovascular disease, the ASCVD event rate was 72.8 (

273 and deaths from cardiovascular diseases and cerebrovascular diseases; the most stable association wa

274 ential role of choline in cardiovascular and cerebrovascular disease through its involvement in lipid

275 tribution of cardiovascular disease (CV) and cerebrovascular disease to the risk for late-onset Alzhe

276 study (six studies on CHD, three studies on cerebrovascular disease, two studies on both coronary he

277 Cerebrovascular disease typically manifests with stroke,

278 Presence of cerebrovascular disease, vascular pathology and vascular

279 Therefore, we compared the prevalence of cerebrovascular disease, vascular pathology and vascular

280 The impact of small-vessel cerebrovascular disease, visualized as white matter hype

281 2, and 3 conditions including PAD, CHD, and cerebrovascular disease was 40.8 (95% confidence interva

282 Preexisting cerebrovascular disease was a potentially modifiable ris

283 When cerebrovascular disease was also present, patients with

284 y of death resulting from cardiovascular and cerebrovascular disease was elevated, 4.2% versus 2.1% a

285 rtion of the association between obesity and cerebrovascular disease was mediated by systolic blood p

286 Cerebrovascular disease was quantified by measuring brai

287 istory of previous strokes, warfarin use, or cerebrovascular disease was recorded.

288 used to identify cases of Parkinsonism where cerebrovascular disease was the only pathological findin

289 ined as use in patients who had a history of cerebrovascular disease, weighed <60 kg, or were aged >/

290 p), the HRs of death from cardiovascular and cerebrovascular disease were 1.5 (95% CI, 1.4 to 1.7) an

291 se overall, acute myocardial infarction, and cerebrovascular disease were 3,500 (95% confidence inter

292 ons, Clinical Modification billing codes for cerebrovascular disease were determined against trial-de

293 Patients with ischemic cerebrovascular disease were enrolled into our study.

294 ognitive impairment, and 280 cases with pure cerebrovascular disease were included for comparison.

295 st more than 18 years old without history of cerebrovascular disease were included.

296 Cases with cerebrovascular disease were older than those without ce

297 the PROGRESS trial, where 6105 patients with cerebrovascular disease were randomly assigned to either

298 ith moyamoya vasculopathy or atherosclerotic cerebrovascular disease who had undergone (15)O-water PE

299 who had a primary or secondary diagnosis of cerebrovascular disease, who underwent magnetic resonanc

300 s generally characterized by the presence of cerebrovascular disease with ocular, renal, and muscular

301 or PAD are similar to those for coronary and cerebrovascular disease, with some differences in the re